- Home
- NOM vs LPCN Comparison
NOM vs LPCN Comparison
Compare NOM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- LPCN
- Stock Information
- Founded
- NOM 1993
- LPCN 1997
- Country
- NOM United States
- LPCN United States
- Employees
- NOM N/A
- LPCN N/A
- Industry
- NOM Investment Managers
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- LPCN Health Care
- Exchange
- NOM Nasdaq
- LPCN Nasdaq
- Market Cap
- NOM 28.0M
- LPCN 27.1M
- IPO Year
- NOM N/A
- LPCN N/A
- Fundamental
- Price
- NOM $11.62
- LPCN $4.60
- Analyst Decision
- NOM
- LPCN Strong Buy
- Analyst Count
- NOM 0
- LPCN 1
- Target Price
- NOM N/A
- LPCN $10.00
- AVG Volume (30 Days)
- NOM 6.9K
- LPCN 32.3K
- Earning Date
- NOM 01-01-0001
- LPCN 03-06-2025
- Dividend Yield
- NOM 3.39%
- LPCN N/A
- EPS Growth
- NOM N/A
- LPCN N/A
- EPS
- NOM N/A
- LPCN N/A
- Revenue
- NOM N/A
- LPCN $7,922,926.00
- Revenue This Year
- NOM N/A
- LPCN N/A
- Revenue Next Year
- NOM N/A
- LPCN N/A
- P/E Ratio
- NOM N/A
- LPCN N/A
- Revenue Growth
- NOM N/A
- LPCN N/A
- 52 Week Low
- NOM $8.52
- LPCN $3.20
- 52 Week High
- NOM $10.48
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- NOM 53.96
- LPCN 44.91
- Support Level
- NOM $11.14
- LPCN $4.25
- Resistance Level
- NOM $11.53
- LPCN $4.89
- Average True Range (ATR)
- NOM 0.27
- LPCN 0.35
- MACD
- NOM -0.06
- LPCN -0.05
- Stochastic Oscillator
- NOM 44.25
- LPCN 28.00
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.